{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:54:23Z","timestamp":1790610863834,"version":"4.1.0"},"reference-count":23,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Grant-in-Aid from the Ministry of Education, Science, Sports and Culture, Japan","award":["22K09814"],"award-info":[{"award-number":["22K09814"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2025,9,11]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/aims<\/jats:title>\n                    <jats:p>This study aimed to investigate the outcomes of intravitreal faricimab (IVF) injection for neovascular age-related macular degeneration (nAMD) and their relationships with clinical findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>At 14 sites, we retrospectively examined the 6-month treatment outcomes of 186 eyes that underwent IVF for treatment-na\u00efve nAMD or nAMD previously treated except for &gt;3 months before the baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Visual acuity and central retinal thickness (CRT) significantly improved at 1, 3 and 6 months after treatment (p&lt;0.001, respectively). At 3 or 6 months, 151 eyes (81.2%) exhibited dry macula. The dry macula rate in the treatment-na\u00efve group (85.7%) was significantly higher than the previously treated group (71.7%, p=0.022). Eyes with pretreatment submacular haemorrhage (SMH) had a significantly higher rate of dry macula (93.9%) than those without (78.4%, p=0.048). Eyes with pretreatment subretinal fluid had good final visual acuity, but poor visual acuity was observed in those with intraretinal fluid (IRF), subretinal hyper-reflective material (SHRM), SMH or hard exudates. However, a similar tendency was also observed at baseline. CRT improvement was good in the eyes with pretreatment IRF, pigment epithelial detachment, SHRM and SMH, although these eyes had higher CRT at the baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IVF treatment for nAMD was associated with improvements in visual acuity and CRT over 6 months. Eyes presenting with SMH showed a higher rate of achieving a dry macula. This result indicates that faricimab may be useful in treating patients with nAMD and SMH. Given the retrospective, non-randomised design, however, these findings should be interpreted cautiously and viewed as hypothesis-generating rather than definitive.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2025-002415","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T10:20:12Z","timestamp":1758795612000},"page":"e002415","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["6-month outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration and their relationships with clinical findings: a multicentre cohort study from the J-CREST"],"prefix":"10.1136","volume":"10","author":[{"given":"Ryoji","family":"Yanai","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Tokushima University, Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Murao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Tokushima University, Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Miki","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Terasaki","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Chujo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Mie University, Tsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Sakaeda","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, Nagoya City University, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyosuke","family":"Seki","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Defense Medical College, Tokorozawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaku","family":"Ishigouoka","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Osaka Medical and Pharmaceutical University Faculty of Medicine Graduate School of Medicine, Takatsuki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Iwase","sequence":"additional","affiliation":[{"name":"Ophthalmology, Akita University Graduate School of Medicine, Akita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Ohara","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, Hiroshima University, Higashihiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tsujinaka","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Nara Medical University, Kashihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5991-3846","authenticated-orcid":false,"given":"Hisashi","family":"Fukuyama","sequence":"additional","affiliation":[{"name":"Hyogo College of Medicine, Nishinomiya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Fukui, Fukui, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nishi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shiga University of Medical Science, Otsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Sapporo City General Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4569-1792","authenticated-orcid":false,"given":"Mineo","family":"Kondo","sequence":"additional","affiliation":[{"name":"Ophthalmology, Mie University Graduate School of Medicine, Tsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0287-3801","authenticated-orcid":false,"given":"Taiji","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Ophthalmology, Kagoshima University, Kagoshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4813-672X","authenticated-orcid":false,"given":"Yoshinori","family":"Mitamura","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Tokushima University, Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"2026010721211582000_10.1.e002415.1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-92567-4","article-title":"Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan","volume":"11","author":"Honda","year":"2021","journal-title":"Sci Rep"},{"key":"2026010721211582000_10.1.e002415.2","article-title":"Age-Related Macular Degeneration: An Exponentially Emerging Imminent Threat of Visual Impairment and Irreversible Blindness","volume":"15","author":"Chaudhuri","year":"2023","journal-title":"Cureus"},{"key":"2026010721211582000_10.1.e002415.3","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/s41433-022-02231-y","article-title":"Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes","volume":"37","author":"Mathis","year":"2023","journal-title":"Eye (Lond)"},{"key":"2026010721211582000_10.1.e002415.4","doi-asserted-by":"crossref","DOI":"10.1038\/srep45081","article-title":"Elevated angiopoietin 2 in aqueous of patients with neovascular age related macular degeneration correlates with disease severity at presentation","volume":"7","author":"Ng","year":"2017","journal-title":"Sci Rep"},{"key":"2026010721211582000_10.1.e002415.5","first-page":"825","article-title":"Faricimab: First Approval","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs (Abingdon Engl)"},{"key":"2026010721211582000_10.1.e002415.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"2026010721211582000_10.1.e002415.7","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.2147\/DDDT.S427416","article-title":"Faricimab: Transforming the Future of Macular Diseases Treatment - A Comprehensive Review of Clinical Studies","volume":"17","author":"Panos","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"2026010721211582000_10.1.e002415.8","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2021.100076","article-title":"TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration","volume":"1","author":"Khanani","year":"2021","journal-title":"Ophthalmol Sci"},{"key":"2026010721211582000_10.1.e002415.9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ajo.2024.10.017","article-title":"Submacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration","volume":"270","author":"Kaufmann","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"2026010721211582000_10.1.e002415.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274508","article-title":"Differences in clinical characteristics and treatment outcomes of submacular hemorrhage caused by age-related macular degeneration and retinal macroaneurysms: A multicenter survey from the Japan Clinical Retina Study (J-CREST) group","volume":"17","author":"Kimura","year":"2022","journal-title":"PLoS One"},{"key":"2026010721211582000_10.1.e002415.11","doi-asserted-by":"crossref","unstructured":"Jaffe GJ , Martin DF , Toth CA , et al . Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2013;1860\u201370. doi:10.1016\/j.ophtha.2013.01.073","DOI":"10.1016\/j.ophtha.2013.01.073"},{"key":"2026010721211582000_10.1.e002415.12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/OPTH.S151999","article-title":"Visual acuity loss associated with excessive \u201cdry macula\u201d in exudative age-related macular degeneration","volume":"12","author":"Takahashi","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"2026010721211582000_10.1.e002415.13","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.oret.2023.06.002","article-title":"Anti-VEGF Treatment Strategies for 3 Subtypes of Neovascular Age-Related Macular Degeneration in a Clinical Setting: A Multicenter Cohort Study in Japan","volume":"7","author":"Yoneda","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"2026010721211582000_10.1.e002415.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0271447","article-title":"Visual prognosis of submacular hemorrhage secondary to age-related macular degeneration: A retrospective multicenter survey","volume":"17","author":"Inoue","year":"2022","journal-title":"PLoS One"},{"key":"2026010721211582000_10.1.e002415.15","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1097\/IAE.0000000000003885","article-title":"PREDICTORS OF 3-MONTH AND 1-YEAR VISUAL OUTCOMES AFTER VITRECTOMY WITH SUBRETINAL TISSUE PLASMINOGEN ACTIVATOR INJECTION FOR SUBMACULAR HEMORRHAGE","volume":"43","author":"Miki","year":"2023","journal-title":"Retina"},{"key":"2026010721211582000_10.1.e002415.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.04.012"},{"key":"2026010721211582000_10.1.e002415.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100906"},{"key":"2026010721211582000_10.1.e002415.18","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1192464","article-title":"Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia\/reperfusion","volume":"17","author":"Canonica","year":"2023","journal-title":"Front Cell Neurosci"},{"key":"2026010721211582000_10.1.e002415.19","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.molmed.2022.03.004","article-title":"Viewpoints: Dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye","volume":"28","author":"Koh","year":"2022","journal-title":"Trends Mol Med"},{"key":"2026010721211582000_10.1.e002415.20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40942-020-00250-z","article-title":"The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye","volume":"6","author":"Nguyen","year":"2020","journal-title":"Int J Retin Vitr"},{"key":"2026010721211582000_10.1.e002415.21","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye (Lond)"},{"key":"2026010721211582000_10.1.e002415.22","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.2147\/OPTH.S231801","article-title":"Angiopoietins as Potential Targets in Management of Retinal Disease","volume":"15","author":"Khanani","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"2026010721211582000_10.1.e002415.23","doi-asserted-by":"crossref","DOI":"10.3390\/cells9081869","article-title":"Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab","volume":"9","author":"Khan","year":"2020","journal-title":"Cells"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2025-002415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:22:13Z","timestamp":1767849733000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2025-002415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,9,25]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/bmjophth-2025-002415"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2025-002415","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}